Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin in clinical practice

A J Hughes1

  • 1Repatriation Hospital, Heidelberg, Victoria, Australia.

Drugs
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Botulinum toxin type A is a safe and effective treatment for conditions with excessive muscle activity, offering relief for focal dystonias and spasms. This therapy provides symptomatic improvement lasting 3-4 months, significantly advancing patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-GeV Electron Acceleration in Wakefields Strongly Driven by Oversized Laser Spots.

Physical review letters·2024
Same author

The Outreach Virtual Fracture Clinic - a Pilot Report of the Initial Nine Months.

Irish medical journal·2023
Same author

National Hip Fracture Incidence - Past, Present and Future Projections.

Irish medical journal·2022
Same author

New Technologies in the Field of Orthopaedic and Spine Surgery - Navigating the Learning Curve

Irish medical journal·2021
Same author

Fixed drug eruption secondary to adalimumab.

Clinical and experimental dermatology·2021
Same author

Tape strips in dermatology research.

The British journal of dermatology·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Botulinum toxin type A is increasingly recognized for treating conditions characterized by excessive muscle activity.
  • Its therapeutic applications have expanded beyond initial indications.

Purpose of the Study:

  • To review the current applications and mechanism of botulinum toxin type A in managing neuromuscular disorders.
  • To highlight its role as a primary treatment for specific conditions.

Main Methods:

  • Review of existing literature on botulinum toxin type A.
  • Description of the mechanism of action involving neuromuscular junction blockade.
  • Discussion of injection techniques, including electrophysiological guidance when necessary.

Main Results:

Related Experiment Videos

  • Botulinum toxin type A is the preferred treatment for focal dystonias (e.g., blepharospasm, torticollis), hemifacial spasm, strabismus, and limb spasticity.
  • Injections block acetylcholine release, reducing muscle activity without significant weakness.
  • Treatment effects are symptomatic, lasting 3-4 months, often requiring repeat injections.

    • Conclusions:

    • Botulinum toxin type A represents a significant therapeutic advance for conditions with poor response to previous therapies.
    • Appropriate use requires understanding muscle physiology and optimal dosing.
    • It offers a safe and effective management option for a growing list of indications.